Please ensure Javascript is enabled for purposes of website accessibility

Acquisitions and International Sales Growth Help Mylan N.V. in Q3

By Keith Speights – Nov 9, 2016 at 1:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The generic and specialty drugmakers continues to face political pressure but posted solid revenue growth in Q3.

Most of the news about Mylan N.V. (MYL) in 2016 has focused on the company's controversial pricing. But the drugmaker was able to change the headlines, if only for a while, when it announced its third-quarter results after the market closed on Wednesday. Here are the highlights from Mylan's quarterly update.

Image source: Getty Images.

Mylan results: The raw numbers


Q3 2016 Actuals

Q3 2015 Actuals

Change (YOY)


$3.06 billion

$2.7 billion


Net income (loss)

($119.8 million)

$428.6 million


Net income (loss) per diluted share




Data source: Mylan. YOY = year over year. 

What happened this quarter?

Third-quarter revenue increased from the prior-year period for a couple of primary reasons: acquisitions and new product launches. Mylan completed its acquisition of the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings in June. Less than two months later, the company wrapped up its purchase of Swedish drugmaker Meda. 

Mylan's generics segment performed better than its specialty business. The company reported third-quarter generics revenue of $2.61 billion, up 17% year over year. Generic drug sales in Europe and the rest of the world increased solidly, but U.S. sales grew only slightly from the prior-year period. This sluggish U.S. generics performance stemmed from lower volumes and selling prices. 

Specialty net product sales declined 4% from the prior-year period to $418.7 million. The major culprit behind this decrease was lower unit volumes due to fewer wholesaler purchases in anticipation of the generic launch of EpiPen.

Mylan posted a GAAP loss in the third quarter primarily because of amortization related to acquisitions and a large settlement with the U.S. government over allegations that the company improperly classified its EpiPen products to pay lower rebates to Medicaid. However, the drugmaker reported non-GAAP earnings of $726.4 million, or $1.38 per share. In the third quarter of 2015, Mylan posted non-GAAP earnings of $733.8 million, or $1.43 per share.

What management had to say

Mylan CEO Heather Bresch said:

Our third quarter results were consistent with the full year guidance we provided a few weeks ago. During the quarter, we reported strong performance across our European and Rest of World regions, as well as solid performance across our North American region despite challenging year-over-year comparisons due to the significant contribution from new products in last year's third quarter. In our Specialty segment, while EpiPen Auto-Injector scripts grew quarter-over-quarter, volumes were down due to the lack of wholesaler purchases in the quarter in anticipation of our upcoming generic launch.

Rajiv Malik, Mylan's president, added:

While our industry continues to evolve, the factors that have always been critical to our success remain constant: maintaining one of the industry's broadest portfolios; consistent execution of new product launches; and being able to reliably supply significant volumes to our customers. Mylan's ability to deliver for customers through the strength of our portfolio and pipeline and reputation for quality and reliability continue to make us a partner of choice.

Looking forward

Mylan reaffirmed its recently updated full-year 2016 adjusted earnings per share guidance of $4.70 to $4.90. The company also still thinks it will achieve its target of 2018 adjusted earnings of $6.00 per share. 

Look for continued political pressure on Mylan, though. The Senate Judiciary Committee is urging federal antitrust regulators to investigate the company. Three members of the committee are also asking Mylan when it will reimburse the Department of Defense for overcharging for its EpiPen injector. All three senators pushing for reimbursement will still be in the U.S. Senate in 2017.

Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Mylan. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.